Conference Coverage

NfL beats T-tau as a prognostic marker of cognitive decline


 

From AAN 2021

An ‘exciting’ prospect

Commenting on the study, Glen R. Finney, MD, director of the Memory and Cognition Program for Geisinger Health in Wilkes-Barre, Pa., said the findings add to neurologists’ ability to screen for brain diseases. “Evidence of neurodegeneration is part of the modern diagnosis of several disorders. While brain imaging can also provide that and may be needed for other reasons, this could provide an easy, potentially inexpensive way to screen for damage to the brain, giving us an added tool,” said Dr. Finney.

The prospect of using blood plasma markers to explore disease of the brain is exciting, Dr. Finney added. “I would like to see ongoing refinement of this approach and would like to see if there’s other markers in blood that could be used to find what specifically may be causing the damage,” he said.

The study was funded by the National Institutes of Health, the National Institute on Aging, and the GHR Foundation. Mr. Marks and Dr. Finney have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Sleep apnea and cognitive impairment are common bedfellows
MDedge Neurology
Palliative care for patients with dementia: When to refer?
MDedge Neurology
Novel Alzheimer’s drug slows cognitive decline in phase 2 trial
MDedge Neurology
Despite risks and warnings, CNS polypharmacy is prevalent among patients with dementia
MDedge Neurology
Cannabinoids promising for improving appetite, behavior in dementia
MDedge Neurology
A paleolithic raw bar, and the human brush with extinction
MDedge Neurology
Simple blood test plus AI may flag early-stage Alzheimer’s disease
MDedge Neurology
Age-related cognitive decline not inevitable?
MDedge Neurology
Are psychiatric disorders a ‘canary in a coal mine’ for Alzheimer’s disease?
MDedge Neurology
Rituximab benefits seen in neuropsychiatric lupus
MDedge Neurology